86
Participants
Start Date
November 29, 2016
Primary Completion Date
March 31, 2019
Study Completion Date
December 2, 2024
Obinutuzumab
1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
Dexamethasone
40 mg D1 to D4 in GA-DHAP
Aracytine
2g/m² D1 \& D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
Cisplatinum
100 mg/m² D1 in GA-DHAP
Etoposide
400 mg/m² D-6 to D-3 in GA-BEAM
Melphalan
140 mg/m² D-2 in GA-BEAM
Carmustine
300 mg/m² D-7 in GA-BEAM
CHU de Caen, Caen
CHU de Dijon - Hôpital le Bocage, Dijon
I.U.C.T Oncopole, Toulouse
CHU de Haut Leveque, Pessac
CHU Montpellier, Montpellier
CHU Pontchaillou, Rennes
CHRU Bretonneau, Tours
CHU de Grenoble, Grenoble
Institut de Cancérologie de Loire, Saint-Priest-en-Jarez
CHU Nantes, Nantes
CHU d'Angers, Angers
CHU Robert Debré, Reims
CHRU Lille - Hôpital Claude Huriez, Lille
CHU de Clermont Ferrand, Clermont-Ferrand
CH Perpignan, Perpignan
CHU de Strasbourg, Strasbourg
CHU Lyon Sud, Pierre-Bénite
Clinique Victor Hugo, Le Mans
Centre Hospitalier Annecy-Genevois, Pringy
Hôpital Saint Louis, Paris
APHP - Hopital Necker, Paris
Centre Henri Becquerel, Rouen
CHU d'Amiens, Amiens
CH d'Avignon, Avignon
CHD Vendée, La Roche-sur-Yon
CHU de Poitiers, Poitiers
CHU Limoges, Limoges
Hopital Henri Mondor, Créteil
Gustave Roussy Cancer Campus, Villejuif
CHU de Brabois, Vandœuvre-lès-Nancy
The Lymphoma Academic Research Organisation
OTHER